- Home
- EPIX vs ABOS Comparison
EPIX vs ABOS Comparison
Compare EPIX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- ABOS
- Stock Information
- Founded
- EPIX 2009
- ABOS 1996
- Country
- EPIX Canada
- ABOS United States
- Employees
- EPIX N/A
- ABOS N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- ABOS Health Care
- Exchange
- EPIX Nasdaq
- ABOS Nasdaq
- Market Cap
- EPIX 65.3M
- ABOS 66.6M
- IPO Year
- EPIX N/A
- ABOS 2021
- Fundamental
- Price
- EPIX $1.71
- ABOS $1.00
- Analyst Decision
- EPIX Hold
- ABOS Strong Buy
- Analyst Count
- EPIX 3
- ABOS 3
- Target Price
- EPIX $2.00
- ABOS $7.33
- AVG Volume (30 Days)
- EPIX 276.9K
- ABOS 213.2K
- Earning Date
- EPIX 05-08-2025
- ABOS 05-13-2025
- Dividend Yield
- EPIX N/A
- ABOS N/A
- EPS Growth
- EPIX N/A
- ABOS N/A
- EPS
- EPIX N/A
- ABOS N/A
- Revenue
- EPIX N/A
- ABOS N/A
- Revenue This Year
- EPIX N/A
- ABOS N/A
- Revenue Next Year
- EPIX N/A
- ABOS N/A
- P/E Ratio
- EPIX N/A
- ABOS N/A
- Revenue Growth
- EPIX N/A
- ABOS N/A
- 52 Week Low
- EPIX $1.40
- ABOS $0.86
- 52 Week High
- EPIX $7.88
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- EPIX 51.16
- ABOS 44.19
- Support Level
- EPIX $1.74
- ABOS $1.00
- Resistance Level
- EPIX $1.85
- ABOS $1.13
- Average True Range (ATR)
- EPIX 0.08
- ABOS 0.10
- MACD
- EPIX -0.01
- ABOS 0.00
- Stochastic Oscillator
- EPIX 13.33
- ABOS 48.33
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.